136 related articles for article (PubMed ID: 30489191)
1. Novel sub-cellular localizations and intra-molecular interactions may define new functions of Mixed Lineage Leukemia protein.
Karole AM; Chodisetty S; Ali A; Kumari N; Tyagi S
Cell Cycle; 2018; 17(24):2684-2696. PubMed ID: 30489191
[TBL] [Abstract][Full Text] [Related]
2. The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds.
Caslini C; Alarcòn AS; Hess JL; Tanaka R; Murti KG; Biondi A
Leukemia; 2000 Nov; 14(11):1898-908. PubMed ID: 11069025
[TBL] [Abstract][Full Text] [Related]
3. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of MLL.
Liedtke M; Cleary ML
Blood; 2009 Jun; 113(24):6061-8. PubMed ID: 19289854
[TBL] [Abstract][Full Text] [Related]
5. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.
Zhu L; Li Q; Wong SH; Huang M; Klein BJ; Shen J; Ikenouye L; Onishi M; Schneidawind D; Buechele C; Hansen L; Duque-Afonso J; Zhu F; Martin GM; Gozani O; Majeti R; Kutateladze TG; Cleary ML
Cancer Discov; 2016 Jul; 6(7):770-83. PubMed ID: 27154821
[TBL] [Abstract][Full Text] [Related]
6. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
7. Taking MLL through the MudPIT: identification of novel complexes that bring together MLL-fusion proteins and transcription elongation factors.
Fromm G; Adelman K
Mol Cell; 2010 Feb; 37(4):449-50. PubMed ID: 20188661
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional activation by MLL fusion proteins in leukemogenesis.
Yokoyama A
Exp Hematol; 2017 Feb; 46():21-30. PubMed ID: 27865805
[TBL] [Abstract][Full Text] [Related]
9. MLL/WDR5 Complex Regulates Kif2A Localization to Ensure Chromosome Congression and Proper Spindle Assembly during Mitosis.
Ali A; Veeranki SN; Chinchole A; Tyagi S
Dev Cell; 2017 Jun; 41(6):605-622.e7. PubMed ID: 28633016
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of MLL-associated leukemia.
Yokoyama A
Int J Hematol; 2015 Apr; 101(4):352-61. PubMed ID: 25773519
[TBL] [Abstract][Full Text] [Related]
11. The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis.
Daser A; Rabbitts TH
Semin Cancer Biol; 2005 Jun; 15(3):175-88. PubMed ID: 15826832
[TBL] [Abstract][Full Text] [Related]
12. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
13. A distinct set of long non-coding RNAs in childhood MLL-rearranged acute lymphoblastic leukemia: biology and epigenetic target.
Fang K; Han BW; Chen ZH; Lin KY; Zeng CW; Li XJ; Li JH; Luo XQ; Chen YQ
Hum Mol Genet; 2014 Jun; 23(12):3278-88. PubMed ID: 24488769
[TBL] [Abstract][Full Text] [Related]
14. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia.
Wang WT; Han C; Sun YM; Chen ZH; Fang K; Huang W; Sun LY; Zeng ZC; Luo XQ; Chen YQ
Clin Cancer Res; 2019 May; 25(9):2795-2808. PubMed ID: 30651276
[TBL] [Abstract][Full Text] [Related]
16. PAFc, a key player in MLL-rearranged leukemogenesis.
Tan J; Muntean AG; Hess JL
Oncotarget; 2010 Oct; 1(6):461-5. PubMed ID: 21037944
[TBL] [Abstract][Full Text] [Related]
17. circRNA circAF4 functions as an oncogene to regulate MLL-AF4 fusion protein expression and inhibit MLL leukemia progression.
Huang W; Fang K; Chen TQ; Zeng ZC; Sun YM; Han C; Sun LY; Chen ZH; Yang QQ; Pan Q; Luo XQ; Wang WT; Chen YQ
J Hematol Oncol; 2019 Oct; 12(1):103. PubMed ID: 31623653
[TBL] [Abstract][Full Text] [Related]
18. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.
Ono R; Nakajima H; Ozaki K; Kumagai H; Kawashima T; Taki T; Kitamura T; Hayashi Y; Nosaka T
J Clin Invest; 2005 Apr; 115(4):919-29. PubMed ID: 15761502
[TBL] [Abstract][Full Text] [Related]
19. Activation of Ras-dependent Elk-1 activity by MLL-AF4 family fusion oncoproteins.
Ng MH; Ng RK; Kong CT; Jin DY; Chan LC
Exp Hematol; 2010 Jun; 38(6):481-8. PubMed ID: 20362031
[TBL] [Abstract][Full Text] [Related]
20. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
